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The P/CAF protein has intrinsic histone acetyltrans-
ferase (HAT) activity and is capable of binding the
transcriptional co-activator CBP. Here we show that
P/CAF can regulate transcription and that this function
is independent of its binding to CBP. The HAT domain
of P/CAF has transcriptional activation potential in
yeast. In mammalian cells P/CAF can stimulate tran-
scription of the RSV promoter, using the activity of its
HAT domain. We show that the adenovirus protein
E1A targets P/CAF and sequesters its transcriptional
activity. Binding of E1A to P/CAF is direct, independent
of CBP and requires residues within E1A conserved
region 1. We find that the P/CAF binding residues in
E1A are within a motif shown to be essential for
efficient disruption of myogenesis by E1A. The fact
that E1A can directly bind and regulate the activity
of P/CAF, independently of its regulation of CBP,





In eukaryotes, transcription of mRNA-encoding class II
genes involves the ordered recruitment of general factors
and the RNA pol II holoenzyme into the basal transcription
pre-initiation complex (Orphanides et al., 1996; Roeder,
1996). This assembly then gives rise to specific, but low-
level gene transcription. This relatively inefficient process
is stimulated by transcriptional activators which bind to
specific DNA sequences outside of the core promoter
(Tjian and Maniatis, 1994). Sequence-specific activators
work in conjunction with other factors which do not contact
DNA directly. These factors are termed co-activators and
are recruited to promoters via their interaction with the
DNA-bound transcription factors (Pugh and Tjian, 1990;
Guarente, 1995).
CBP and p300 are distinct but functionally related
co-activator proteins, involved in both proliferative and
differentiating pathways, and which interact with numer-
ous sequence-specific transcription factors including
CREB (Chrivia et al., 1993), c-Fos (Bannister and
Kouzarides, 1995), c-Jun (Bannister et al., 1995), c-Myb
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(Dai et al., 1996), Stat1 and 2 (Bhattacharya et al., 1996),
MyoD (Eckner et al., 1996), NFκB p65 (Perkins et al.,
1997), E2F1 (Trouche et al., 1996), p53 (Gu and Roeder,
1997) and nuclear hormone receptors (Kamei et al.,
1996). In addition, CBP/p300 also complex with other co-
activators such as ACTR (Chen et al., 1997) and SRC-1
(Smith et al., 1996; Yao et al., 1996), with the adenoviral
transforming protein E1A (Eckner et al., 1994) and with
the P/CAF protein (Yang et al., 1996).
The mechanism for the CBP/p300-mediated stimulation
of transcription is not yet clear. The CBP/p300 proteins
contain multiple activation domains and can contact the
basal transcription factors TBP and TFIIB (Kwok et al.,
1994; Yuan et al., 1996). Consequently, it was suggested
that the CBP/p300 proteins increase transcription by
bridging sequence-specific activators to the basal transcrip-
tional machinery, thereby stabilizing the pre-initiation
complex whilst adding to it additional activation domains
(Kwok et al., 1994). However, the overall picture is more
complex because of the recent observation that both
CBP and p300 possess intrinsic nucleosomal histone
acetyltransferase (HAT) activity (Bannister and
Kouzarides, 1996; Ogryzko et al., 1996). Moreover, other
co-activators which complex with CBP/p300, such as
P/CAF (Yang et al., 1996), ACTR (Chen et al., 1997) and
SRC-1 (Spencer et al., 1997), themselves contain intrinsic
nucleosomal HAT activity.
In vivo the transcriptional machinery has to transcribe
DNA which is tightly associated with histones in nucleo-
somal arrays (reviewed in Grunstein, 1997). Packaging
DNA into this type of structure represses transcription.
Stimulation (or more precisely, derepression) of transcrip-
tion requires remodelling of the chromatin, and correlates
with the acetylation of specific lysines within the N-
termini of nucleosomal histones (reviewed by Loidl, 1994).
This acetylation neutralizes the basic charge of the lysines
and causes a repositioning of the histone N-termini where-
upon new protein–protein contacts are initiated. The net
result is a weakening of the nucleosomal and higher order
protein–DNA structure. In vivo a strong correlation exists
between the hyperacetylation of histone N-termini and
active genes (Hebbes et al., 1988; Turner and O’Neill,
1995), and conversely, between hypoacetylation of his-
tones and transcriptionally inactive genes (reviewed by
Pazin and Kadonaga, 1997). Thus, it seems likely that co-
activator proteins with intrinsic HAT activity would use
this activity to stimulate transcription. Interestingly, the
known co-activators capable of acetylating nucleosomal
histones, CBP/p300, P/CAF, ATCR/SRC-1 and TAFII250,
show varied substrate specificity (Bannister and
Kouzarides, 1996; Mizzen et al., 1996; Yang et al., 1996;
Chen et al., 1997; Spencer et al., 1997) suggesting a
mechanism to fine-tune transcriptional responses.
E1A protein is encoded by the small DNA tumour
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virus, adenovirus. By interaction with cellular proteins
E1A pushes cells through their cell cycle, thereby facilitat-
ing virus reproduction (for reviews see Moran, 1993;
Jones, 1995). A consequence of prolonged E1A expression
within mammalian cells is cellular transformation. For
this effect, E1A requires two distinct domains within its
N-terminus. One domain binds members of the pocket-
containing protein family, the most characterized of which
is the Rb tumour suppressor protein (Moran, 1993; Jones,
1995). The second domain binds members of the CBP/
p300 family of co-activators (Moran, 1993; Jones, 1995).
Via these interactions, E1A relieves growth suppression
and inhibits cellular differentiation, for example myo-
genesis.
CBP/p300-mediated transcriptional activity can be
abrogated by E1A (Arany et al., 1995; Bannister and
Kouzarides, 1995; Lundblad et al., 1995). The mechanism
by which this repression occurs may involve sequestration
of CBP/p300 away from the promoter. Alternatively, E1A
may displace a CBP/p300-associated factor which is
required for efficient activation of transcription. Since
E1A displaces the CBP/p300-associated factor P/CAF
from the co-activator complex (Yang et al., 1996), it is
possible that P/CAF displacement results in a loss of CBP/
p300-dependent transcription.
P/CAF was originally identified as a CBP/p300-binding
protein by virtue of its sequence similarity to a yeast HAT,
namely yGCN5 (Yang et al., 1996). The proteins show
considerable sequence conservation, especially in two
regions; one of these regions is responsible for full HAT
activity in yGCN5 and the second is required for yGCN5
to bind the yADA2 co-factor (Yang et al., 1996; Candau
et al., 1997; Wang et al., 1997). Indeed, a human homo-
logue of yADA2 has been identified (hADA2; Candau
et al., 1996) which may be important for P/CAF function.
In vitro yGCN5 efficiently acetylates free histones in
solution, but does not recognize nucleosomal histones as
substrate (Brownell et al., 1996; Yang et al., 1996).
However, in vivo, yGCN5 is found in a large multisubunit
complex containing yADA2 and yADA3 (Candau and
Berger, 1996; Grant et al., 1997). Within this complex,
yGCN5 is the HAT enzymatic component and now
acetylates nucleosomal histones (Grant et al., 1997).
In contrast, P/CAF has an intrinsic ability to acetylate
nucleosomal histones in vitro, even though it has retained
the ADA2 binding site (Yang et al., 1996). It is possible
that in vivo, hADA2 may alter the specificity of P/CAF’s
nucleosomal HAT activity.
Since P/CAF itself has intrinsic nucleosomal HAT
activity, we asked whether P/CAF is able to stimulate
transcription. Here we present evidence that P/CAF is
indeed a transcriptional activator protein. Its ability to
stimulate transcription is independent of CBP/p300 but
is dependent on P/CAF’s intrinsic HAT activity. The
adenoviral E1A oncoprotein binds directly to P/CAF
and abrogates P/CAF-induced transcription. These results
indicate that E1A can bind and regulate independently the
activity of two different HATs, namely CBP and P/CAF.
Moreover, we find that E1A mutated in a previously
characterized motif (Sandmo¨ller et al., 1996), which is
essential for E1A inhibition of myogenesis, has reduced
binding to P/CAF. Since P/CAF itself is essential for
myogenesis (Puri et al., 1998) our results are consistent
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Fig. 1. The P/CAF HAT domain has activation potential in yeast.
Various P/CAF domains were fused to the LexA DNA-binding domain
and transformed into yeast. P/CAF-HATΔ contains a 20 amino acid
deletion (Δ528–547). The reporter contains LexA DNA-binding sites
upstream of the bacterial lacZ gene. β-galactosidase activity was
determined by standard techniques. Activity is indicated by degree
with ‘’ signs, with ‘’ indicating highest activity (deep blue
colour in 15 min in a filter lacZ assay) and ‘–’ indicating
background activity (remaining white after 5 h). The LexA–P/CAF
fusions were all expressed to equivalent levels, as determined by
Western blotting (data not shown). The same P/CAF domains were
expressed as GST fusions and their intrinsic HAT activity measured by
liquid HAT assays. An equivalent amount of each GST–P/CAF fusion
was assayed (~500 ng) as determined by Coomassie Blue staining.
HAT activity for each fusion was normalized relative to the activity
for GST alone (expressed as fold over GST).
with a model in which E1A, at least in part, represses
myogenesis by inactivating the functions of P/CAF.
Results
P/CAF stimulates transcription independently of
CBP
Many different transcription factors recruit CBP to pro-
moters, resulting in enhanced transcription. The currently
held model is that these transcription factors may also
recruit P/CAF to promoters by virtue of its interaction
with CBP. We wanted to establish whether P/CAF had
activator functions independent of CBP. Therefore, we
sought to identify the region of P/CAF harbouring HAT
enzyme activity and then to ask whether the activity is
sufficient to activate transcription, independently of CBP.
To this end, we expressed various domains of P/CAF as
GST fusions and tested whether they could acetylate free
histones in solution assays. Figure 1 clearly shows that
P/CAF 352–658 has full enzyme activity. GST fusions
which do not include this region have no HAT activity.
Thus, we refer to P/CAF 352–658 as the P/CAF HAT
domain. These data are in very close agreement with the
recently reported minimumHAT domain of yGCN5, which
shares significant homology with P/CAF (Candau et al.,
1997). An in-frame deletion of amino acids 528–547
within the HAT domain completely abrogates HAT activity
(Figure 1).
Given the strong correlation that exists between the
acetylation state of chromatin and transcriptionally active
DNA, we asked whether the HAT activity residing within
P/CAF is sufficient to stimulate transcription. To ensure
that we were monitoring CBP-independent HAT activity,
P/CAF-stimulated transcription is abrogated by E1A
we asked whether P/CAF could stimulate transcription in
yeast where there is no CBP. Figure 1 shows that P/CAF
can stimulate transcription when fused to the LexA DNA
binding domain, and that the domain carrying HAT activity
(352–658) is sufficient for this function. Moreover, a
functional HAT activity is essential to activate transcription
since the deletion in the HAT domain, which abrogates
HAT activity, also completely abrogates its ability to
activate transcription.
Having established that P/CAF has a CBP-independent
transcriptional activation potential, we sought to establish
whether P/CAF could activate transcription of mammalian
promoters. Previous CBP–P/CAF binding studies (Yang
et al., 1996) had strongly implicated the N-terminus of
P/CAF as the region which binds CBP. To ensure that our
assays would monitor CBP-independent P/CAF activity,
we generated a P/CAF mutant (P/CAF-CT) lacking the
N-terminal CBP-binding residues. Figure 2B shows that
deletion of the P/CAF N-terminus does indeed abrogate
the binding of CBP to P/CAF.
Since P/CAF is likely to be recruited to the promoter
by as yet unidentified DNA-bound transcription factors,
we asked whether P/CAF could stimulate complex viral
promoters. Figure 2C shows that P/CAF can stimulate the
RSV-LTR in transient transfection assays in MRC-5 cells.
Other viral promoters, such as the HIV-LTR, are also
activated by P/CAF (data not shown). This activation
capacity is independent of CBP, since P/CAF-CT is
sufficient for this activity. Indeed, a minimal P/CAF HAT
domain (amino acids 352–652) is sufficient for this effect,
albeit with a slightly reduced efficiency (~60% of full-
length activity). The observed 3- to 5-fold activation by
P/CAF is very similar to the levels of induction observed
with CBP on a variety of promoters (Eckner, 1996 and
references therein). The HAT activity of P/CAF is essential
for the stimulation of the RSV promoter since a deletion
in the HAT domain that destroys HAT activity (Figure 1)
completely abrogates its ability to stimulate transcription
(Figure 2C). These results establish that P/CAF has the
ability to stimulate transcription via its HAT domain
and that this stimulation is independent of its ability to
bind CBP.
E1A directly contacts P/CAF
The viral E1A protein and P/CAF bind to overlapping
sites within CBP. Consequently, E1A can displace P/CAF
from CBP (Yang et al., 1996). This displacement has been
proposed to be the mechanism behind the antagonistic
effect of P/CAF and E1A on cell-cycle progression (Yang
et al., 1996). However, given that P/CAF has CBP-
independent co-activator function, we considered the pos-
sibility that E1A may directly target and inactivate P/CAF
function. We first asked if E1A could contact P/CAF
directly and independently of CBP. Various E1A constructs
were expressed as GST fusion proteins and we determined
whether they could bind in vitro translated and radio-
labelled P/CAF protein. Figure 3A shows that P/CAF
binds efficiently to GST–E1A but not to GST alone. The
E1A N-terminus (amino acids 1–90) encompassing CR1
(amino acids 40–80) is sufficient for this interaction. P/
CAF does not bind to E1A CR2 or CR3. An E1A N-
terminal mutant (E1A 1–90 CBP MUT, Figure 3A, lane
6), which no longer binds to CBP (Wong and Ziff, 1994;
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Fig. 2. P/CAF stimulates transcription from the RSV-CAT reporter,
independently of CBP. (A) A schematic representation of the P/CAF
constructs used, showing the position of the HAT domain, the ADA2
binding domain (based on homology to GCN5) and the 20 amino acid
deletion (Δ528–547) in P/CAF-HATΔ. (B) A P/CAF construct deleted
of its N-terminus no longer binds CBP in vitro. Either GST or GST–
CBP2 was incubated with in vitro translated, 35S-radiolabelled P/CAF-
FL (left panel) or P/CAF-CT (right panel) and subjected to GST pull-
down. Lane 1 in each case shows 25% of the P/CAF input. (C) MRC5
cells were transfected with 2 μg of the RSV-CAT reporter and 2 μg of
either P/CAF, P/CAF-CT, P/CAF-HAT, P/CAF-HATΔ or equivalent
empty vector. Whole-cell extracts were used in CAT assays and the
results quantified on a phosphoimager. The activity derived from the
RSV-CAT reporter plus empty vector was normalized to 1.0 and the
other activities expressed relative to this. All the P/CAF proteins were
expressed to similar levels, as determined by Western blotting (data
not shown). The data shown is an average of at least three
independent transfections.
Bannister and Kouzarides, 1995; Trouche and Kouzarides,
1996) still binds P/CAF efficiently. This indicates that the
in vitro translated P/CAF is not binding to the GST–E1A
via CBP present in the lysate. Indeed, the contact between
P/CAF and E1A is direct rather than via any other
intermediary proteins present in the lysate, since GST–P/
CAF binds efficiently to a bacterially expressed and
radiolabelled E1A 1–90 domain (Figure 3B). This is
further supported by the observation that E1A interacts
with P/CAF in yeast (in a two-hybrid interaction assay)
where there is no CBP (Figure 3C).
The interaction between P/CAF and E1A can also be
observed in vivo by employing a co-immunoprecipitation
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Fig. 3. P/CAF interacts with E1A in vitro and in vivo. (A) GST–E1A
binds P/CAF in vitro. A schematic representation of E1A 13S showing
the position of conserved regions 1, 2 and 3 (CR1, 2 and 3) and the
mutation in the CBP binding site (CBP MUT). The various GST
fusions as indicated were incubated with in vitro translated,
35S-radiolabelled P/CAF and subjected to GST pull-down. Lane 8
shows 25% of the P/CAF input. (B) E1A1-90 binds P/CAF directly.
Bacterially expressed GST, GST–P/CAF or GST–P/CAF-CT were
incubated with bacterially expressed, 32P-labelled E1A1-90 protein and
subjected to GST pull-down. (C) P/CAF interacts with E1A in a yeast
two-hybrid assay. Either the LexA–DBD alone or a LexA–P/CAF100-
832 fusion were co-transformed into yeast cells with E1A 13S fused to
the VP16 activation domain, or pVP16 alone. β-galactosidase activity
was determined by standard techniques and quantified relative to the
activity of LexA-P/CAF100-832 alone (‘–’ means no detectable β-gal
activity, ‘’ represents the activity of LexA–P/CAF100-832 (see
Figure 1) and ‘’ represents a 300% increase in activity).
Expression of LexA–P/CAF100-832 and VP16–E1A13S, in the
appropriate yeast strains, was confirmed by Western blotting (data not
shown). (D) E1A co-immunoprecipitates with P/CAF from extracts of
transfected U2OS cells. Cells were transfected with 10 μg each of
pCX–P/CAF (expresses Flag-tagged P/CAF) and pBJ9Ω–E1A12S (or
the E1A12S–CBP binding mutant) as indicated. Whole-cell extracts
were precipitated with the M2 (αFlag) antibody and the presence of
E1A in the immunoprecipitates was visualized by Western blot
analysis with the M73 (αE1A) antibody. Expression of the appropriate
proteins in each extract was confirmed by Western blotting of the cell
lysates with the M2 (αFlag) and M73 (αE1A) antibodies (data not
shown).
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Fig. 4. The P/CAF HAT domain binds E1A in a yeast two-hybrid
interaction. Various LexA–P/CAF fusions were co-transformed into
yeast cells with either a VP16–E1A13S fusion or VP16 alone.
β-galactosidase activity was determined by standard techniques. The
intrinsic activity (with VP16 alone) was normalized for each construct
and the activity with VP16–E1A13S expressed relative to this (‘–’
means no increase in activity and ‘’ an ~300% increase in activity).
The LexA–P/CAF fusions were all expressed to equivalent levels, as
determined by Western blotting (data not shown). Expression of
VP16–E1A13S, in the appropriate yeast strains, was confirmed by
Western blotting (data not shown).
approach. E1A 12S or an E1A12S CBP-binding mutant
(E1A CBPMUT) and Flag-tagged P/CAF were transfected
together into U2OS cells. An anti-Flag antibody was used
to immunoprecipitate Flag-tagged P/CAF from whole-cell
extracts and then anti-E1A antibodies were used to detect
E1A (or the E1A CBP MUT) following Western blotting
of the immunoprecipitate (Figure 3D, lanes 3 and 4).
Both E1A and E1A CBP MUT were efficiently co-
immunoprecipitated by the anti-Flag antibodies indicating
that (i) P/CAF and E1A form a complex in vivo and (ii)
CBP does not mediate this interaction. The interaction
was not observed when either P/CAF or E1A were
transfected alone (Figure 3D, lanes 1 and 2). The P/CAF–
E1A interaction is also seen if we immunoprecipitate E1A
and Western blot for P/CAF (data not shown).
A yeast two-hybrid assay was employed to determine
which region of P/CAF contacted E1A. Various deletions
of P/CAF were expressed in yeast as LexA DBD fusions
and we asked whether they were capable of interacting
with an E1A.VP16 fusion. Figure 4 shows that the N-
terminus of P/CAF (1–352) or the C-terminal residues
containing the bromodomain (695–832) are not required
for E1A binding. A central P/CAF domain, containing the
HAT and ADA2 sites, is sufficient to bind E1A. The same
results were obtained in in vitro binding assays employing
GST–P/CAF and in vitro translated and radiolabelled E1A
(data not shown).
Binding of E1A to P/CAF does not affect P/CAF
HAT activity
Given that E1A binds the HAT domain of P/CAF, we
next sought to determine whether E1A binding affected the
intrinsic P/CAF HAT activity. GST–P/CAF was incubated
with a 10-fold molar excess of either GST–E1A or GST
alone (Figure 5A) under conditions which allow efficient
E1A binding to P/CAF. In a liquid HAT assay, the activity
of GST–P/CAF was not affected by the presence of excess
E1A (Figure 5A).
By employing an IP-HAT assay approach, we also
observed no effect of E1A on P/CAF HAT activity derived
from mammalian cell-expressed P/CAF. Flag-tagged
P/CAF, in the presence or absence of E1A, was transiently
P/CAF-stimulated transcription is abrogated by E1A
Fig. 5. Binding of E1A to P/CAF does not affect P/CAF HAT activity in vitro or in vivo. (A) Approximately 500 ng of GST–P/CAF was pre-
incubated with a 10-fold molar excess of either GST or GST–E1A13S. The HAT activity of the GST–P/CAF or a GST control was then measured in
a liquid HAT assay. (B) U2OS cells were transfected with 10 μg of pCX–P/CAF (expresses Flag-tagged P/CAF) and increasing amounts of pBJ9Ω–
E1A12S (0, 5, 10 and 20 μg). Whole-cell extracts were precipitated with M2 αFlag antibody (F) and the immune complexes tested for their ability
to acetylate free histones. The HAT activity associated with the M2 antibody in the absence of transfected P/CAF is shown in column 1 and the
activity associated with a non-specific antibody (HA) is shown in column 6.
transfected into U2OS cells. Exogenous P/CAF was then
immunoprecipitated with an anti-Flag antibody and the
HAT activity present within the immunopellet was deter-
mined using a liquid HAT assay. Significant activity was
pelleted with the Flag antibody only when P/CAF was
transfected (Figure 5B). A control antibody (anti-HA) did
not immunoprecipitate HAT activity. Co-transfection of
E1A with P/CAF had no effect on the level of P/CAF
HAT activity, even at the highest concentration of E1A
employed (Figure 5B).
E1A represses P/CAF-mediated activation
Although we observed no effect of E1A on P/CAF’s HAT
activity, we wished to know whether E1A could affect
the functional activity of P/CAF. More specifically, we
asked whether E1A affected P/CAF’s ability to stimulate
the RSV promoter. Figure 6A clearly demonstrates that
E1A efficiently abrogates the ability of P/CAF to stimulate
this promoter. Moreover, the CR1 domain of E1A is
essential for E1A’s repression of P/CAF, since deletion of
this region severely abrogates E1A’s ability to suppress
the P/CAF dependent activation (Figure 6A). An E1A
mutant that no longer binds CBP represses P/CAF-induced
activation to the same extent as wild-type E1A 12S (data
not shown) indicating that under these conditions E1A
does not repress P/CAF via an interaction with CBP.
Since the HAT domain of P/CAF is sufficient to activate
the RSV promoter (Figure 2) we next sought to determine
whether E1A is able to abrogate this activity. Figure 6B
shows that E1A efficiently abrogates the ability of the
P/CAF HAT domain to activate transcription from the
RSV promoter, indicating that the P/CAF HAT domain
contains determinants which allows targeting by E1A. This
is in perfect agreement with our P/CAF–E1A interaction
assays (Figures 3C and D, and 4).
It has been known for some time that both the CBP/
p300 and Rb families of proteins are involved in myogen-
esis. Whilst the work presented here was in progress, it
was reported that P/CAF activity is also essential for
muscle-specific enhancer function and muscle differenti-
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ation (Puri et al., 1998). The E1A protein can block
myogenesis and Sandmo¨ller et al. (1996) have identified
a motif within the CR1 region of E1A (amino acids 55–
60) which is required for E1A’s ability to block myogen-
esis. E1A proteins containing mutations within this motif
still interact with CBP/p300 and Rb (Sandmo¨ller et al.,
1996). Given P/CAF binds the CR1 domain of E1A
(Figure 3), we sought to establish whether the motif
(amino acids 55–60) within E1A CR1 which is required
for E1A’s anti-myogenic effect, is also required for binding
P/CAF. A co-immunoprecipitation approach was used to
test for P/CAF binding to an E1A protein mutated in this
region (E1A E55 mutant). Wild-type E1A 12S, E1A E55
mutant, or a control E1A 12S Rb binding mutant (E1A
RB MUT) were transfected along with Flag-tagged
P/CAF into U2OS cells. An anti-E1A antibody was used
to immunoprecipitate the E1A proteins from whole-cell
extracts and then an anti-Flag antibody was used to detect
P/CAF following Western blotting of the immunoprecipi-
tate. Figure 7B shows that E1A 12S and E1A 12S RB
MUT efficiently bind to P/CAF but that the E1A E55
mutant is severely compromised in P/CAF binding. Densi-
tometric analysis of this data showed that P/CAF binding
was reduced by 75% (data not shown). In all cases,
the levels of P/CAF and E1A proteins were equivalent
(Figure 7; data not shown). These results indicate that
residues 55–60 within CR1 are involved in binding
P/CAF. These residues are not involved in binding CBP/
p300 or Rb (Sandmoller et al., 1996; data not shown).
Thus, the disruption of P/CAF binding correlates with the
ability of E1A to suppress myogenesis.
Discussion
Here we show that P/CAF has the ability to stimulate
gene transcription in a CBP-independent manner and that
this activity requires P/CAF’s intrinsic HAT activity.
The requirement for P/CAF HAT activity to stimulate
transcription is in excellent agreement with similar data
obtained using a yeast homologue of P/CAF, namely
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Fig. 6. E1A represses P/CAF-mediated activation. (A) MRC5 cells
were transfected with 2 μg of the RSV-CAT reporter, 2 μg pCX–P/
CAF or equivalent empty vector and 2 μg of either pBJ9Ω–E1A12S
or the empty pBJ9Ω vector. Whole-cell extracts were used in CAT
assays and the results quantified on a phosphoimager. The activity
derived from the RSV-CAT reporter plus empty vectors was
normalized to 1.0 and the other activities expressed relative to this.
The E1A12S and E1A12S–ΔCR1 proteins were expressed to similar
levels, as determined by Western blotting (data not shown). The data
shown are an average of at least three independent transfections.
(B) The experiment was performed essentially as in (A), except 2 μg
of the P/CAF–HAT construct (described in Figure 2), which does not
bind CBP, was used instead of full-length P/CAF.
yGCN5 (Kuo et al., 1998; Wang et al., 1998). Our results
establish P/CAF as a co-activator protein, whose activity
may be required for the stimulation of certain promoters.
The fact that P/CAF and CBP are likely to act independ-
ently as co-activators raises the question of promoter
selectivity. It is possible that these two HATs are recruited
to different promoters by distinct sets of promoter-targeting
transcription factors. Indeed, our preliminary analysis of
cellular promoter targets for P/CAF indicates that P/CAF
is unlikely to be a ‘promiscuous’ co-activator like CBP.
Several of the cellular promoters stimulated by CBP are
not affected by P/CAF (data not shown).
The need for two independent HAT activities may result
from the fact that CBP and P/CAF preferentially acetylate
distinct histones in vitro (Bannister and Kouzarides, 1996;
Ogryzko et al., 1996; Yang et al., 1996). This may
lead to differential ‘activated’ states necessary for some
promoters but not others. However, the fact that a propor-
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Fig. 7. P/CAF binds to E1A residues that are required for E1A to
block myogenesis. (A) A schematic representation of E1A12S showing
the positions of CR1 and CR2, the RB binding site mutation
(RB MUT) and the region mutated within E1A E55. Equal expression
of E1A wild type, E1A RB MUT and E1A E55, after transfection of
the relevant expression plasmids into U2OS cells, was confirmed by
Western blotting with the M73 (αE1A) antibody. E1A E55 binds Rb
and CBP at levels equivalent to E1A wild type (Sandmo¨ller et al.,
1996; data not shown). (B) U2OS cells were transfected with 10 μg
each of pCX–P/CAF and pBJ9Ω–E1A12S (or E1A RB MUT or E1A
E55) as indicated. Whole-cell extracts were precipitated with 2 μg of
the M73 (αE1A) antibody and the presence of P/CAF in the
immunoprecipitates was visualized by Western blot analysis with the
M2 (αFLAG) antibody (right panel). Prior to immunoprecipitation, 2%
of the lysates were removed and Western blotted with the M2
(αFLAG) antibody to confirm that P/CAF expression in the three
lysates was equivalent (left panel). The three E1A proteins were
expressed to equivalent levels (Figure 7A; data not shown). The
experiment was repeated and the same decrease in P/CAF binding to
E55 observed. The panels display non-contiguous lanes from the same
Western blot of a single experiment.
tion of P/CAF protein is found complexed with CBP
(Yang et al., 1996) suggests that some promoters may
require the combined stimulatory effect of both HATs.
This combinatorial HAT activity may lead to synergistic
activation of transcription.
Another complexity to the target specificity of these
HATs is raised by the recent observation that non-histone
proteins are substrates for HAT activity. The fact that
transcription factors such as p53 (Gu and Roeder, 1997)
and basal factors such as TFIIE (Imhof et al., 1997) are
acetylated by CBP and P/CAF, suggests that HATs may
stimulate transcription by regulating the activity of pro-
moter-bound targets. If such mechanisms operate, then it
is conceivable that P/CAF may have a different and more
limited target specificity than CBP, leading to the activation
of a specific subset of promoters.
Adenovirus requires cellular proliferation for its own
replication. Consequently, one of its proteins, the trans-
forming protein E1A, has evolved to steer cells through
the cell cycle. E1A uses two distinct but essential domains
to transform mammalian cells (Moran, 1993; Jones, 1995).
One domain directs binding to the RB-pocket protein
family resulting in loss of growth suppression, whilst the
second domain directs binding to the p300/CBP family
of coactivators, leading to a loss of p300/CBP-induced
differentiation, for example myogenesis. Here we have
shown that E1A can also efficiently block P/CAF-mediated
P/CAF-stimulated transcription is abrogated by E1A
transcription independently of CBP. Exactly how E1A
blocks P/CAF transcriptional activity is not clear. Since
E1A binds to the P/CAF HAT domain, the most simple
model would involve E1A inactivating the HAT enzymatic
activity. However, this does not appear to be the case
as the P/CAF–E1A complex retains full HAT activity
(Figure 5). This is consistent with the observation that
the CBP–E1A complex also retains full HAT activity
(Bannister and Kouzarides, 1996; data not shown) even
though E1A represses CBP’s ability to activate transcrip-
tion. One model would be that E1A masks the binding or
recognition for a non-histone substrate of P/CAF HAT
activity. An alternative, but not mutually exclusive
explanation is that E1A sequesters P/CAF away from the
promoter. In this scenario, the E1A binding site in P/CAF
may overlap with the binding site for transcription factors
that target P/CAF to the promoter. This model of promoter
sequestration has been proposed for the ability of E1A to
inactivate CBP function. For CBP this model is bolstered
by the fact that the E1A binding site is also the binding
site for a variety of transcription factors which recruit
CBP to the promoter (reviewed in Eckner, 1996). The
E1A binding site in CBP is situated proximally to the
HAT domain, a situation reflected in P/CAF (Figure 4).
Thus, the region overlapping the HAT domain of P/CAF
is likely to harbour the binding site for the transcription
factors which recruit P/CAF to the promoter. Yeast two-
hybrid screens are currently being used to identify such
promoter targeting factors.
Many factors influence the process of muscle differenti-
ation, including the Rb family of proteins, CBP/p300 and
the transcription factor MyoD. E1A actively represses
muscle differentiation, at least in part, by targeting Rb
and CBP/p300. Recently, P/CAF was also shown to be
essential for stimulating the myogenic pathway (Puri et al.,
1998). E1A can repress P/CAF-mediated muscle-specific
enhancer activation and myogenic differentiation (Puri
et al., 1998). Mutants of E1A have already been character-
ized which fail to block myogenesis efficiently, even
though they still retained the ability to contact CBP/p300
and Rb (Sandmo¨ller et al., 1996). Furthermore, a region
within E1A (amino acids 40–61) which does not bind
CBP/p300 or Rb is necessary and sufficient for the
repression of muscle-specific enhancers (Sandmo¨ller et al.,
1996). In particular, a six amino acid motif (amino acids
55–60) is necessary for this effect. Here we show that
mutagenesis of E1A residues 55–60 disrupts the binding
to P/CAF. The fact that this mutant does not completely
abolish binding to P/CAF may be an indication that a
second P/CAF binding site exists in E1A CR1. The
incomplete loss of binding is also consistent with the
biological data which show that mutating amino acids 55–
60 in E1A CR1 is only partially effective in disrupting
the myogenic blockage (Sandmoller et al., 1996). Taken
together these data strongly suggest that the E1A E55
mutant is unable to override the process of muscle differen-
tiation because it has lost the capacity to associate stably
with the P/CAF protein. Thus P/CAF must have an
important role to play in differentiation since a viral




HAT and IP-HAT assays
Liquid HAT and IP-HAT assays were performed essentially as described
previously (Bannister and Kouzarides, 1996).
Cell culture, transfections and CAT assays
U2OS cells were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) with 10% fetal calf serum (FCS) and grown at 37°C, 5% CO2.
MRC5 cells (ECACC No. 84101801) were maintained in minimum
essential media with non-essential amino acids and 10% FCS and grown
at 37°C, 5% CO2. Cells were transfected by the calcium phosphate co-
precipitation method and CAT assays performed according to standard
methods.
In vivo expression plasmids
pCX–P/CAF has been described previously (Yang et al., 1996). P/CAF-
CT and P/CAF-HAT were cloned from pCX–P/CAF, by PCR, into the
pcDNA3 vector (Invitrogen). The P/CAF-HATΔ mutant (deletion of
amino acids 528–547) was made from P/CAF-HAT using the Quick
Mutagenesis Kit (Stratagene) and checked by DNA sequencing. Both
P/CAF-HAT and P/CAF-HATΔ have an N-terminal Gal4 epitope. All
Ad5 E1A12S constructs were expressed from plasmid pBJ9Ω, an RSV-
driven expression vector (gift from H.Land). The Ad5 E1A12S CBP
and Rb binding mutants have been described previously (Bannister and
Kouzarides, 1995; Trouche and Kouzarides, 1996; Trouche et al., 1996).
The CBP mutant contains a deletion of amino acids 64–68 and has been
shown to be defective in binding CBP in vivo (Wong and Ziff, 1994).
The Rb mutant has amino acids 38–44 converted to alanine and has
been shown to not bind to Rb in vivo (Trouche and Kouzarides, 1996).
The E55 mutant was made from pBJ9ΩAd5 E1A12S using the Quick
Mutagenesis Kit (Stratagene) and checked by DNA sequencing. The
E55 mutant has amino acids 55–60 mutated to alanine. This six amino
acid motif has been shown to be essential for E1A to block myogenesis
efficiently and mutations in this region do not affect E1A binding to Rb
or CBP/p300 (Sandmo¨ller et al., 1996). It was confirmed that the E1A
E55 mutant bound to Rb and CBP at levels equivalent to wild type (data
not shown).
GST fusion proteins
Various domains of P/CAF and Ad5 E1A were cloned into the pGex-
2TK vector (provided by W.Kaelin) using PCR. pGex-4T2-P–CAF-FL
was a gift from Pino Santarelli and Maurizia Caruso. pGex2TKP–
CBP2 has been described previously (Bannister and Kouzarides, 1995).
Recombinant proteins were expressed in and purified from Escherichia
coli XA90 as reported previously (Bannister et al., 1991).
In vitro translations and pull-down assays
In vitro translations and GST pull-downs were performed essentially as
described previously (Hagemeier et al., 1993). The buffer used for the
pull-downs was a variation of Z (25mM HEPES pH 7.5, 12.5 mM
MgCl2, 20% glycerol, 0.1% NP-40, 250 mM KCl). For the direct
interaction experiment, pGexE1A1-90 was radiolabelled with 32P accord-
ing to Kaelin et al. (1992) and cleaved from GST with thrombin (Sigma).
Immunoprecipitations and Western analysis
Co-immunoprecipitations and Western analysis were performed, essen-
tially as described previously (Lavender et al., 1997) but with several
modifications. 15 cm dishes of U2OS cells were transfected with 10 μg
of each expression vector and lysed in 1 ml of IPH lysis buffer (Bannister
and Kouzarides, 1996) 36–48 h post-transfection. Immunoprecipitations
were performed using standard procedures. Antibodies used were α-Flag
(M2 affinity gel and M2 monoclonal antibody, Kodak), α-E1A (M73,
Santa Cruz) and α-HA (12CA5, Boehringer Mannheim). For the immuno-
precipitations in Figure 7, the washes were performed in IPH buffer
with 500 mM salt.
Yeast plasmids, activation and two-hybrid assays
Various deletions of P/CAF were cloned, by PCR, into the LexA DNA
binding domain vector pBTM116 (Vojtek et al., 1993). pVP16 E1A 13S
and pVP16 E1A1-90 were cloned by PCR into the pVP16 vector (Vojtek
et al., 1993 ). The activation and two-hybrid assays were performed in
yeast strain L40. Yeast transformation was carried out as described
previously (Kaiser et al., 1994) and β-galactosidase assays were per-
formed using standard techniques.
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